AQNEURSA

Growth

levacetylleucine

NDAORALFOR SUSPENSIONPriority Review

Approved

Sep 2024

Lifecycle

Growth

Competitive Pressure

0/100

Mechanism of Action

P-Glycoprotein Inhibitors

Indications (1)

neurological manifestations of Niemann-Pick disease type C (NPC) in adults

Loss of Exclusivity

LOE Date

Apr 19, 2037

135 months away

Patent Expiry

Apr 19, 2037

Exclusivity Expiry

Sep 24, 2031

Patent Records (3)

Patent #	Expiry	Type	Use Code
11400067	Apr 19, 2037		U-4170
12433862	Apr 19, 2037		U-4284
12433863	Apr 19, 2037		U-4285

Company

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers